Sep / 2025

OncoDaily IO OncoDaily GI Hemostasis Today

Insight

Oct 31, 2023 10:22 am

Oct 31, 2023 9:39 am

Oct 29, 2023 5:31 pm

Oct 29, 2023 3:56 am

Oct 28, 2023 4:36 pm

Oct 28, 2023 3:23 pm

Oct 28, 2023 3:09 am

Oct 27, 2023 4:48 am

Oct 27, 2023 4:23 am

Oct 27, 2023 4:06 am

…

769

…

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Insight

5 Decades of Impact reflection series – Australasian Leukaemia and Lymphoma Group

Paolo A. Ascierto: The history of melanoma is changing!

Diego Adrianzen-Herrera: Our study on MDS and autoimmune disease in Blood Advances

Enrique Soto: The new ASCO and ESMO global curriculum recommendations for Cancer Care in older adults

Vinay Prasad: The most interesting thing you’ll read about PFS, EFS, DFS in oncology this year

Bente Mikkelsen: How to formulate a global response to cancer through partnership and co-creation

Sandra Algarín-Perneth: The success of precision oncology guided by HER2 genomic profiling – a rare neuroendocrine carcinoma case

Sumanta K. Pal: Eloquent discussion from Andrea Apolo National Cancer Institute synthesizing data from EV302 and CM901

The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population – CUHK Medicine

Joosje Baltussen: 64-76% of older patients treated with chemotherapy have poor outcomes after 1 year

Headlines

Insight

5 Decades of Impact reflection series – Australasian Leukaemia and Lymphoma Group

Paolo A. Ascierto: The history of melanoma is changing!

Diego Adrianzen-Herrera: Our study on MDS and autoimmune disease in Blood Advances

Enrique Soto: The new ASCO and ESMO global curriculum recommendations for Cancer Care in older adults

Vinay Prasad: The most interesting thing you’ll read about PFS, EFS, DFS in oncology this year

Bente Mikkelsen: How to formulate a global response to cancer through partnership and co-creation

Sandra Algarín-Perneth: The success of precision oncology guided by HER2 genomic profiling – a rare neuroendocrine carcinoma case

Sumanta K. Pal: Eloquent discussion from Andrea Apolo National Cancer Institute synthesizing data from EV302 and CM901

The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population – CUHK Medicine

Joosje Baltussen: 64-76% of older patients treated with chemotherapy have poor outcomes after 1 year

Headlines

OncoDaily

Oncology

cancer

fight against cancer

Global fight against cancer

cancer care

Breast Cancer

ASCO

Lung cancer

Cancer research

MD Anderson Cancer Center

cancer awareness

NSCLC

ESMO

immunotherapy

cancer treatment

Research

ASCO24

Headlines

colorectal cancer

Childhood Cancer

prostate cancer

AACR

clinical trials

FDA

Dana-Farber Cancer Institute

UICC

American Cancer Society

European Cancer Organisation

NCI

National Cancer Institute

healthcare

SIOP

ASCO25

chemotherapy

Vivek Subbiah

AI

American Society of Clinical Oncology

Paolo Tarantino

IASLC

WHO

Robert Orlowski

multiple myeloma

Memorial Sloan Kettering Cancer Center

Zainab Shinkafi-Bagudu

radiation oncology

Myeloma Paper of the Day

cervical cancer

Myeloma

patient care

European School of Oncology

Sitemap